Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report

We investigated the effect of the functional insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene on the response to interferon-β (IFN-β) therapy in Croatian and Slovenian patients with multiple sclerosis (MS). A total of 275 IFN-β treated MS patients [162 responders...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmacogenetics and genomics Jg. 27; H. 6; S. 232
Hauptverfasser: Ristić, Smiljana, Starčević Čizmarević, Nada, Lavtar, Polona, Lovrečić, Luca, Perković, Olivio, Sepčić, Juraj, Šega Jazbec, Saša, Kapović, Miljenko, Peterlin, Borut
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States 01.06.2017
Schlagworte:
Adult
Antineoplastic Agents - therapeutic use
Croatia
Female
Gene Frequency
Genotype
Humans
INDEL Mutation
Interferon-beta - therapeutic use
Male
Multiple Sclerosis - drug therapy
Multiple Sclerosis - genetics
Peptidyl-Dipeptidase A - genetics
Pharmacogenomic Variants
Slovenia
Treatment Outcome
Young Adult
ISSN:1744-6880, 1744-6880
Online-Zugang:Weitere Angaben
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract We investigated the effect of the functional insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene on the response to interferon-β (IFN-β) therapy in Croatian and Slovenian patients with multiple sclerosis (MS). A total of 275 IFN-β treated MS patients [162 responders (Rs) and 113 nonresponders (NRs)] were genotyped by PCR. The ACE I/D genotype distribution and allele frequencies did not differ between female Rs and NRs. However, male NRs tended to have a greater prevalence of the DD genotype (P=0.073; odds ratio: 2.64; 95% confidence interval: 0.91-7.60) and a significantly higher frequency of the D allele (P=0.022; odds ratio: 2.43; 95% confidence interval: 1.13-5.20) than male Rs. Multiple forward stepwise regression analysis indicated that the negative response to IFN-β therapy was associated with the ACE-DD genotype in men (β=0.371; multiple R change: 0.132; P=0.009) and a higher pretreatment relapse rate in both men (β=-0.438; multiple R change: 0.135; P=0.015) and women (β=-0.208; multiple R change: 0.042; P=0.034). The ACE I/D polymorphism and pretreatment relapse rate accounted for ∼26.7% of the IFN-β response variability among the men in the sample. Further studies of a larger number of MS patients from different populations are necessary to evaluate these preliminary findings.
AbstractList We investigated the effect of the functional insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene on the response to interferon-β (IFN-β) therapy in Croatian and Slovenian patients with multiple sclerosis (MS). A total of 275 IFN-β treated MS patients [162 responders (Rs) and 113 nonresponders (NRs)] were genotyped by PCR. The ACE I/D genotype distribution and allele frequencies did not differ between female Rs and NRs. However, male NRs tended to have a greater prevalence of the DD genotype (P=0.073; odds ratio: 2.64; 95% confidence interval: 0.91-7.60) and a significantly higher frequency of the D allele (P=0.022; odds ratio: 2.43; 95% confidence interval: 1.13-5.20) than male Rs. Multiple forward stepwise regression analysis indicated that the negative response to IFN-β therapy was associated with the ACE-DD genotype in men (β=0.371; multiple R change: 0.132; P=0.009) and a higher pretreatment relapse rate in both men (β=-0.438; multiple R change: 0.135; P=0.015) and women (β=-0.208; multiple R change: 0.042; P=0.034). The ACE I/D polymorphism and pretreatment relapse rate accounted for ∼26.7% of the IFN-β response variability among the men in the sample. Further studies of a larger number of MS patients from different populations are necessary to evaluate these preliminary findings.We investigated the effect of the functional insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene on the response to interferon-β (IFN-β) therapy in Croatian and Slovenian patients with multiple sclerosis (MS). A total of 275 IFN-β treated MS patients [162 responders (Rs) and 113 nonresponders (NRs)] were genotyped by PCR. The ACE I/D genotype distribution and allele frequencies did not differ between female Rs and NRs. However, male NRs tended to have a greater prevalence of the DD genotype (P=0.073; odds ratio: 2.64; 95% confidence interval: 0.91-7.60) and a significantly higher frequency of the D allele (P=0.022; odds ratio: 2.43; 95% confidence interval: 1.13-5.20) than male Rs. Multiple forward stepwise regression analysis indicated that the negative response to IFN-β therapy was associated with the ACE-DD genotype in men (β=0.371; multiple R change: 0.132; P=0.009) and a higher pretreatment relapse rate in both men (β=-0.438; multiple R change: 0.135; P=0.015) and women (β=-0.208; multiple R change: 0.042; P=0.034). The ACE I/D polymorphism and pretreatment relapse rate accounted for ∼26.7% of the IFN-β response variability among the men in the sample. Further studies of a larger number of MS patients from different populations are necessary to evaluate these preliminary findings.
We investigated the effect of the functional insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene on the response to interferon-β (IFN-β) therapy in Croatian and Slovenian patients with multiple sclerosis (MS). A total of 275 IFN-β treated MS patients [162 responders (Rs) and 113 nonresponders (NRs)] were genotyped by PCR. The ACE I/D genotype distribution and allele frequencies did not differ between female Rs and NRs. However, male NRs tended to have a greater prevalence of the DD genotype (P=0.073; odds ratio: 2.64; 95% confidence interval: 0.91-7.60) and a significantly higher frequency of the D allele (P=0.022; odds ratio: 2.43; 95% confidence interval: 1.13-5.20) than male Rs. Multiple forward stepwise regression analysis indicated that the negative response to IFN-β therapy was associated with the ACE-DD genotype in men (β=0.371; multiple R change: 0.132; P=0.009) and a higher pretreatment relapse rate in both men (β=-0.438; multiple R change: 0.135; P=0.015) and women (β=-0.208; multiple R change: 0.042; P=0.034). The ACE I/D polymorphism and pretreatment relapse rate accounted for ∼26.7% of the IFN-β response variability among the men in the sample. Further studies of a larger number of MS patients from different populations are necessary to evaluate these preliminary findings.
Author Lovrečić, Luca
Šega Jazbec, Saša
Kapović, Miljenko
Lavtar, Polona
Sepčić, Juraj
Peterlin, Borut
Ristić, Smiljana
Starčević Čizmarević, Nada
Perković, Olivio
Author_xml – sequence: 1
  givenname: Smiljana
  surname: Ristić
  fullname: Ristić, Smiljana
  organization: aDepartment of Biology and Medical Genetics bSchool of Medicine, University of Rijeka cDepartment of Neurology, Clinical Hospital Center Rijeka, Rijeka, Croatia dClinical Institute of Medical Genetics eDepartment of Neurology, University Medical Centre, Ljubljana, Slovenia
– sequence: 2
  givenname: Nada
  surname: Starčević Čizmarević
  fullname: Starčević Čizmarević, Nada
– sequence: 3
  givenname: Polona
  surname: Lavtar
  fullname: Lavtar, Polona
– sequence: 4
  givenname: Luca
  surname: Lovrečić
  fullname: Lovrečić, Luca
– sequence: 5
  givenname: Olivio
  surname: Perković
  fullname: Perković, Olivio
– sequence: 6
  givenname: Juraj
  surname: Sepčić
  fullname: Sepčić, Juraj
– sequence: 7
  givenname: Saša
  surname: Šega Jazbec
  fullname: Šega Jazbec, Saša
– sequence: 8
  givenname: Miljenko
  surname: Kapović
  fullname: Kapović, Miljenko
– sequence: 9
  givenname: Borut
  surname: Peterlin
  fullname: Peterlin, Borut
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28430710$$D View this record in MEDLINE/PubMed
BookMark eNpNkM1KAzEUhYMoaqtvIJKlm2mTTGYm464Uq4KgC12XdOa2RvJnkgr1WXwKH8RnMsUKvZt7uHzncLgDdGidBYQuKBlR0jbj2dN0RPaHifIAndKG86IWghzu6RM0iPGNkLJuOTtGJ0zwkjSUnKKviV0pl8BGZYvO2Q8ISdkVBvu5MYCVjduDs-MeNGwFXoEF7J3eGBf8q4oGS9tnMEFYQnC2-PnGKYBMBmzCAaJ3OSQD2Kx1Ul4Djp3OZFQRe5lUxuI1ltgH0MooK8Mm27wL6QwdLaWOcL7bQ_Qyu3me3hUPj7f308lD0bGGlkW_oIS2sGDLThDOGdRdKUohm7IWFauAsqqTy6ahTNQV5VSIvqVtL-uay-wt2RBd_eX64N7XENPcqNiB1tKCW8c5FS2lnIuKZ_Ryh64XBvq5D8rkwvP_j7JfOLd_rw
CitedBy_id crossref_primary_10_1016_j_intimp_2018_09_014
crossref_primary_10_1134_S0026893319040149
crossref_primary_10_1177_1470320320957157
ContentType Journal Article
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1097/FPC.0000000000000283
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1744-6880
ExternalDocumentID 28430710
Genre Journal Article
GroupedDBID ---
.Z2
0R~
123
4Q1
4Q2
4Q3
53G
5VS
8L-
AAAAV
AAHPQ
AAIQE
AAMTA
AARTV
AASCR
AAYOK
ABASU
ABBUW
ABDIG
ABJNI
ABVCZ
ABXVJ
ABZAD
ACDDN
ACEWG
ACGFO
ACGFS
ACILI
ACWDW
ACWRI
ACXJB
ACXNZ
ADGGA
ADHPY
ADNKB
AE3
AE6
AEETU
AENEX
AFDTB
AFUWQ
AHQNM
AHRYX
AHVBC
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AWKKM
BQLVK
C45
CGR
CS3
CUY
CVF
DIWNM
DU5
DUNZO
E.X
EBS
ECM
EEVPB
EIF
EJD
EX3
F2K
F2L
F5P
FCALG
FL-
GNXGY
GQDEL
HLJTE
HZ~
IKREB
IN~
IPNFZ
JF9
JG8
KD2
KMI
L-C
NPM
O9-
OAG
OAH
OCUKA
OJAPA
OL1
OLV
OLW
OLZ
OPC
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OWU
OWV
OXXIT
P2P
RIG
RLZ
S4S
T8P
TEORI
TSPGW
V2I
VVN
W3M
WOQ
WOW
X3V
X3W
ZFV
ZZMQN
7X8
ABPXF
ABZZY
ACBKD
ADKSD
AFBFQ
AOQMC
ID FETCH-LOGICAL-c2713-db1019eb2fc80442e6c3838a7368525e125caf771286514188d919da664adb132
IEDL.DBID 7X8
ISSN 1744-6880
IngestDate Sun Nov 09 11:18:08 EST 2025
Wed Feb 19 02:41:34 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 6
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2713-db1019eb2fc80442e6c3838a7368525e125caf771286514188d919da664adb132
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 28430710
PQID 1891144854
PQPubID 23479
ParticipantIDs proquest_miscellaneous_1891144854
pubmed_primary_28430710
PublicationCentury 2000
PublicationDate 2017-June
PublicationDateYYYYMMDD 2017-06-01
PublicationDate_xml – month: 06
  year: 2017
  text: 2017-June
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Pharmacogenetics and genomics
PublicationTitleAlternate Pharmacogenet Genomics
PublicationYear 2017
SSID ssj0036942
Score 2.238436
Snippet We investigated the effect of the functional insertion/deletion (I/D) polymorphism in the angiotensin-converting enzyme (ACE) gene on the response to...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage 232
SubjectTerms Adult
Antineoplastic Agents - therapeutic use
Croatia
Female
Gene Frequency
Genotype
Humans
INDEL Mutation
Interferon-beta - therapeutic use
Male
Multiple Sclerosis - drug therapy
Multiple Sclerosis - genetics
Peptidyl-Dipeptidase A - genetics
Pharmacogenomic Variants
Slovenia
Treatment Outcome
Young Adult
Title Angiotensin-converting enzyme insertion/deletion gene polymorphism and interferon-β treatment response in multiple sclerosis patients: a preliminary report
URI https://www.ncbi.nlm.nih.gov/pubmed/28430710
https://www.proquest.com/docview/1891144854
Volume 27
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3BTtwwELValgMXWqBQSkGDhDhhbeIkjsMFIcSKS1c5gLS3lRM7KBLrLElBCt_Sr-iH9Js6dpLdUyWk5hDl4sjSzHjeeGbeEHKWBYjBVZRRTwechuiAqJB-RnWeFV6gGCJs5YZNxNOpmM2StL9wa_qyyuFMdAe1qnJ7Rz72BZolxhJReLV8pnZqlM2u9iM0PpJRgFDGGmY8W2URAp644TkIukPKUVGH1rkkHk_Sm466cHiYJQ78F8h0zmby6X-3-Zls9zATrju92CEftNkl52nHU91ewP267aq5gHNI1wzW7R75dW0ey8rVthvq6tIt18AjaPPWLjSUxqbwUaBjO0XHfgCqoYZl9dQuKhRc2SxAGgWWi6IudF0Z-uc3rGraoe4Kc-2fYKhohAY3ii67bKDnem0uQcKy1k9u8FjdQpff-EIeJrf3N3e0H-NAc4YhMFUZmn2CEXyRCy8MmeY5hsVCxpb7nkUaIVYuizj2bZOsH_pCqMRPlOQ8lLg2YPtkw1RGfyXAeZTkQqoYtSjM_EhyXzGRsUR7GkM375CcDlKZo5nY3Ic0unpp5mu5HJKDTrTzZcfnMUcPHVik9e0dq4_IFrOO3d3DfCejAg8JfUw289efZVOfOP3D9zT98Rfx0elS
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Angiotensin-converting+enzyme+insertion%2Fdeletion+gene+polymorphism+and+interferon-%CE%B2+treatment+response+in+multiple+sclerosis+patients%3A+a+preliminary+report&rft.jtitle=Pharmacogenetics+and+genomics&rft.au=Risti%C4%87%2C+Smiljana&rft.au=Star%C4%8Devi%C4%87+%C4%8Cizmarevi%C4%87%2C+Nada&rft.au=Lavtar%2C+Polona&rft.au=Lovre%C4%8Di%C4%87%2C+Luca&rft.date=2017-06-01&rft.issn=1744-6880&rft.eissn=1744-6880&rft.volume=27&rft.issue=6&rft.spage=232&rft_id=info:doi/10.1097%2FFPC.0000000000000283&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1744-6880&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1744-6880&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1744-6880&client=summon